What is the best treatment for calcific tendinopathy of the shoulder with associated subacromial and subdeltoid bursitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Calcific Tendinopathy with Subacromial-Subdeltoid Bursitis

Start with a subacromial corticosteroid injection combined with physical therapy as first-line treatment, followed by ultrasound-guided barbotage with needling if symptoms persist after 6-8 weeks, reserving surgery for patients who fail both interventions.

Initial Management Approach

The presence of subacromial-subdeltoid bursitis alongside calcific tendinopathy creates an inflammatory component that requires targeted treatment. While the AAOS guidelines provide only inconclusive recommendations for corticosteroid injections in rotator cuff pathology 1, the specific context of calcific tendinopathy with active bursitis warrants a more aggressive initial approach.

First-Line Treatment (0-8 weeks)

  • Subacromial corticosteroid injection with local anesthetic
    • The 2020 AAOS guidelines support moderate evidence for single corticosteroid injections providing short-term pain and functional improvement in shoulder pain 2
    • Target the inflamed bursa directly to address the inflammatory component
    • Combine with structured physical therapy program focusing on range of motion and rotator cuff strengthening

Critical caveat: The presence of bursitis is a negative prognostic factor. Recent evidence demonstrates that patients with subacromial-subdeltoid bursitis have significantly worse outcomes after extracorporeal shockwave therapy (mean NRS 6.29 vs 3.36, DASH 44.09 vs 19.35, p<0.05) 3. This suggests the inflammatory bursal component must be addressed directly for optimal outcomes.

Second-Line Treatment (8-12 weeks if first-line fails)

  • Ultrasound-guided barbotage with needling
    • This minimally invasive technique shows 63-75% success rates in avoiding surgery 4, 5
    • Most effective for soft, middle-sized calcifications (12-17mm) 6
    • Provides rapid pain relief through mechanical disruption and lavage of calcium deposits
    • Success rates: PT (59%), CSI (75%), USB (72%) - no significant difference between modalities 5

Important warning: Monitor for acute calcific bursitis after barbotage, which can occur when calcium fragments migrate into the bursa 7. If pain worsens acutely post-procedure, repeat ultrasound and consider additional barbotage of the bursal space.

Prognostic Factors to Consider

Your patient's specific characteristics matter significantly:

  • Age: Younger patients (30-40 years) respond better to percutaneous treatment 6
  • Calcification characteristics: Soft calcifications with incomplete acoustic shadow respond better than hard calcifications with complete shadow 3, 6
  • Size: Middle-sized deposits (12-17mm) have better outcomes; deposits >10mm or >3cm are more likely to require surgery 6, 8
  • Duration: Chronic symptoms >8 months predict surgical need 8
  • Gender: Female patients are more likely to require surgery 8

When to Proceed to Surgery

Surgical indications (arthroscopic calcium removal with bursectomy):

  • Failure of both corticosteroid injection AND barbotage
  • Patients attempting multiple nonoperative modalities (100% eventually require surgery) 5
  • Large calcifications >3cm or multiple tendon involvement 5
  • Symptoms >8 months with failed conservative treatment 8

The good news: surgical outcomes are not negatively influenced by previous nonoperative management attempts, so there is no harm in exhausting conservative options first 5.

Treatment Algorithm Summary

  1. Week 0: Subacromial corticosteroid injection + physical therapy
  2. Week 6-8: Reassess - if >50% improvement, continue PT; if <50% improvement, proceed to barbotage
  3. Week 12-16: If barbotage fails or symptoms recur, consider surgical referral
  4. Red flags for early surgery: Female, >8 months duration, calcification >10mm, failed steroid response 8

Avoid: Multiple sequential nonoperative modalities without clear improvement - this 100% predicts eventual surgical need and delays definitive treatment 5. Do not pursue more than two distinct nonoperative approaches before surgical consultation.

The presence of bursitis in your case makes addressing the inflammatory component critical and may predict a more challenging treatment course 3.

References

1
Guideline

optimizing the management of rotator cuff problems.

The Journal of the American Academy of Orthopaedic Surgeons, 2011

2
Guideline

management of rotator cuff injuries.

The Journal of the American Academy of Orthopaedic Surgeons, 2020

8
Research

Calcific tendonitis of the shoulder; when should we operate?

Annals of the Royal College of Surgeons of England, 2026

Related Questions

What is the recommended treatment for calcific peritendinitis?
What is the postoperative care plan for a patient who underwent right shoulder arthroscopy with labral debridement, glenoid and humeral head chondroplasty, biceps tenotomy and tenodesis, subacromial decompression with bursectomy, and calcific tendinitis debridement?
Is the information about laser facial resurfacing applicable to Korean glass‑skin laser treatments?
What is the appropriate evaluation and management for an 80‑year‑old woman presenting with mild orthostatic dizziness, new memory impairment, poor appetite, and recent bereavement?
The patient has a blood pressure of 137/91 mm Hg while on amlodipine 10 mg; should I add another calcium‑channel blocker?
What is the latest treatment for chronic immune thrombocytopenia (ITP)?
What are the current recommended treatment options for an adult with chronic immune thrombocytopenia (ITP) refractory to a brief course of corticosteroids?
Has chlorthalidone been recalled?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.